Treating insomnia in chronic pain fixes sleep more than pain

It’s 3 a.m., and your knee has woken you again. Lying there, the logic feels airtight: get the arthritis under control and the nights will take care of themselves.

The research paints a less tidy picture. A 2022 review in BMC Musculoskeletal Disorders opens by noting that about two-thirds of people with chronic pain report problems sleeping. When researchers track both over weeks and years, a bad night more often predicts a worse day than the other way around. Yet when trials treat the insomnia directly, sleep improves a great deal and pain improves a little, often not for long.

That mismatch is the useful part. It means poor sleep deserves treatment in its own right, not as a footnote to pain care. And for people who take opioids or other sedating medicines, the night carries a separate risk, in how they breathe, that no bedtime routine touches.

Which comes first, the bad night or the bad day?

For years the standard view was that sleep and pain simply worsen each other. A 2013 review in The Journal of Pain by Patrick H Finan and colleagues at Johns Hopkins examined the newer studies that tracked people over time and tested both directions. The authors summed it up this way: “Out of 9 recent prospective studies that have tested both directional effects, 6 found stronger evidence for the temporal precedence of sleep over pain.”

In plain terms, poor sleep usually did more to predict later pain than pain did to predict later poor sleep. The authors called this a trend, not a rule, and named an exception. An earlier review had found effects running both ways in most of the studies it examined. Large population studies added another piece. Insomnia symptoms raised the odds that people who started out pain-free would develop chronic pain, while existing pain did a poor job of predicting who would develop new insomnia.

Experiments point the same way but leave a gap. A 2022 meta-analysis in Sleep Medicine Reviews found 31 experimental studies of sleep loss and pain, involving 699 healthy volunteers but only 47 people with chronic pain. In healthy people, cutting sleep raised pain sensitivity, on limited to moderate evidence; in people already living with chronic pain, the authors judged the findings uncertain.

One small experiment Finan’s review describes shows why the pattern of sleep may matter as much as the amount. Healthy women, 10 per group, were woken repeatedly through an eight-hour night. The next day they reported more pain, and their bodies dampened pain less effectively, than women who got the same total sleep in one unbroken stretch. Broken sleep is exactly what pain tends to cause: the review notes that frequent nighttime awakenings are the main sleep complaint of people with chronic pain. How an overprotective nervous system can turn up pain is explored in our central sensitization article.

Federal research agencies still treat the practical question as open. In December 2024 the National Heart, Lung, and Blood Institute (NHLBI) and two other parts of the National Institutes of Health held a workshop on sleep and pain. Organizers described sleep problems as frequent companions of conditions from osteoarthritis and neuropathy to sickle cell disease and fibromyalgia, and called the relationship two-way. One of the workshop’s stated goals was to examine whether sleep treatments should be built into pain management.

So the sleep-first idea has evidence pointing its way, but how to read that evidence is still argued over, which is the verdict this library calls positive evidence, contested interpretation. It rests mostly on observational studies, which show timing, not proof of cause.

Treating the insomnia works for sleep

The treatment most tested in people with pain is cognitive behavioral therapy for insomnia (CBT-I), a short structured course that resets sleep schedules and the habits and worries that keep insomnia going. What insomnia guidelines say about it, and how firmly, is set out in our article on sleep across the decades. The question here is whether it works when pain is part of the picture.

It does, about as well as it works without pain. A 2025 meta-analysis in JAMA Internal Medicine pooled 67 randomized trials with 5,232 people living with chronic diseases, including chronic pain, cancer, irritable bowel syndrome and stroke. CBT-I produced a large improvement in insomnia severity and moderate gains in how efficiently people slept and how fast they fell asleep. The authors judged the effects comparable to those in people without chronic disease and similar across disease types. On average 13.3% dropped out, and treatment-related side effects were rare.

The largest US trial in pain shows what that looks like in practice. A 2021 JAMA Internal Medicine study led by Susan M McCurry of the University of Washington recruited 327 adults aged 60 and older with insomnia and osteoarthritis pain, statewide through Kaiser Permanente Washington. One group received six telephone sessions of CBT-I, each 20 to 30 minutes, spread over eight weeks; the other got education about sleep and arthritis.

• Two months after treatment: scores on a standard insomnia severity scale fell 8.1 points with CBT-I against 4.8 with education alone.
• A year later: 56.3% of the CBT-I group remained in remission from insomnia, compared with 25.8% of the comparison group. Fatigue also stayed lower.
• Cost: a 2022 economic analysis of the same trial counted about 89 more insomnia-free nights per person over the year, with no significant change in total health care costs.

The 2022 BMC review reached a matching conclusion across 42 trials: CBT-I clearly improved sleep quality in people with chronic pain. Sleep hygiene advice on its own showed no evidence of benefit, and some head-to-head studies favored CBT-I over it. Even so, a 2026 review in Osteoarthritis and Cartilage observed that disturbed sleep is very common in osteoarthritis yet seldom addressed in routine care.

Treating the insomnia helps pain less, and not for long

Here the hope that better sleep will melt the pain runs into the trial data. The McCurry trial reported it in one line: “Posttreatment significant differences were observed for pain, but these differences were not sustained at 12-month follow-up.”

A 2015 Johns Hopkins trial in Arthritis & Rheumatology, led by Michael T Smith, went further by using a convincing placebo. It assigned 100 people with knee osteoarthritis and insomnia to eight sessions of either CBT-I or behavioral desensitization, an active placebo therapy built to look like real treatment. CBT-I cut nighttime waking more, measured by diaries and by in-home sleep recordings. Pain, though, fell about equally in both groups over six months, with roughly a third reporting at least 30% less pain. People whose night waking dropped early tended to report less pain later, a link that was stronger with CBT-I.

The pooled evidence tells the same story in numbers:

• A 2021 meta-analysis of 12 trials and 762 people in Sleep Medicine Reviews found a post-treatment effect size of 0.89 for sleep but just 0.20 for pain. Expressed as probabilities, the chance of less pain after CBT-I was about 58% right after treatment and 57% at follow-up of up to a year, where 50% would mean no effect at all. For better sleep, the same figures were 81% and 71%.
• A 2022 network meta-analysis of 16 trials found CBT-I beat control conditions for pain, disability and depression right after treatment, while warning that the studies were small and at high risk of bias.
• In fibromyalgia, a 2025 meta-analysis in the journal Pain found CBT-I did not significantly reduce pain compared with usual care.

That earns CBT-I’s effect on pain the library’s verdict of measured but below the threshold that matters: real at times, small, and short-lived. The honest trade-off runs the other way, too. A treatment that gives you back most of your nights without a pill is worth having even if the pain score barely moves.

Treating the pain doesn’t reliably fix the sleep

The mirror-image belief, that sleep will follow once the pain is managed, fares no better. In the 2022 network meta-analysis, CBT aimed at pain did not beat control conditions on any outcome, sleep included. A 2025 review in Rheumatology covering 47 trials and 11,094 people with fibromyalgia found the same split: CBT-I improved sleep quality, while CBT for pain had no significant effect on it. Results for medicines in that review were mixed and uncertain, and the authors urged caution about drug risks.

Some psychological pain programs have nudged sleep scores as a side benefit, a detail our article on psychological pain treatments takes up. The broader lesson holds: sleep problems in pain usually need to be targeted directly. Trials that combined CBT-I with pain-focused CBT did improve sleep, which hints that the sleep component carried that result.

Fibromyalgia shows why this matters. The National Institute of Arthritis and Musculoskeletal and Skin Diseases lists trouble sleeping among the condition’s main symptoms, alongside widespread pain and fatigue. How fibromyalgia is diagnosed is left to its own entry.

The nighttime breathing risk in some pain medicines

This is the layer that sleep tips never reach. FDA-approved labeling for opioid pain medicines, such as the morphine label revised in December 2023, warns that opioids can cause sleep-related breathing disorders, including central sleep apnea and low blood oxygen during sleep. In central sleep apnea, breathing pauses because the body briefly makes no effort to breathe, unlike obstructive apnea, where the airway closes. The label tells prescribers that for patients who develop it, they can consider lowering the dose using best practices for tapering, a decision that belongs with the prescriber.

How common is it? A 2015 review in Anesthesia & Analgesia gathered eight studies of 560 long-term opioid users who had overnight sleep studies and found central sleep apnea in 24% of them. Severity rose with dose, sedating sleep medicines or benzodiazepines were tied to worse severity in one study, and standard CPAP machines often failed to correct it. Those were people who had sleep studies, often for a reason, so 24% is not a rate for everyone taking opioids.

The harm question has a twist. A 2021 review in the same journal noted that no direct evidence yet shows major clinical consequences from this breathing pattern itself in long-term opioid users. Its authors suggested it may even be a protective adjustment. What is well documented is the danger of stacking sedating drugs:

• Opioids plus benzodiazepines or other sedatives, including alcohol. Opioid labels carry a boxed warning, the FDA’s most serious kind, that the combination can cause profound sedation, slowed breathing, coma and death.
• Gabapentin or pregabalin with opioids or other sedatives. In December 2019 the FDA warned of serious breathing problems with these nerve-pain drugs in people with respiratory risk factors. Those include taking opioids or other central nervous system depressants, lung conditions such as chronic obstructive pulmonary disease, and older age. The agency required new warnings on the labels.
• Higher opioid doses. In July 2025 the FDA reported that in studies it required, a higher baseline dose was the strongest and most consistent predictor of opioid overdose. The same update added gabapentin and pregabalin to opioid interaction warnings and noted that opioids can paradoxically increase pain.

None of this is a reason to change a medicine on your own. The FDA’s 2025 update warns that cutting opioids quickly or stopping them abruptly has led to serious withdrawal, uncontrolled pain and suicide. Sleep medicines carry their own risks for older adults, which our coverage of long-term sleep research details. Whether opioids relieve back pain at all is weighed in the back pain article.

What to raise with your prescriber

The NHLBI suggests keeping a sleep diary for one to two weeks before an appointment about sleep, noting bedtimes, wake times, naps, caffeine, alcohol and exercise. For pain, add a nightly note of how many times pain woke you. The agency also says clinicians may ask whether you snore loudly or wake gasping, and that a sleep study can look for sleep apnea and other disorders.

Questions worth bringing:

1. Could anything I take be affecting my breathing at night? List everything, including opioids, gabapentin or pregabalin, benzodiazepines, sleep aids and alcohol.
2. Has anyone heard me snore, gasp or stop breathing? If a bed partner has, ask whether a sleep study makes sense.
3. Do any of my medicines add up? Ask specifically whether the combination, not just each drug, raises breathing risk for someone like you.
4. Can I get CBT-I, and in what form? Ask about phone, video or online options and what your plan covers.
5. How will we track sleep and pain separately? Two scores make it clear which treatment is doing what.
6. If my medicines ever change, what is the plan? The FDA warns against rapid cuts made without a clinician.

Whether any dose changes, and how fast, is a decision for you and the clinician who prescribes it.

When not to wait

Call 911 if someone who takes an opioid, gabapentin, pregabalin, a benzodiazepine or a sleep medicine has slowed or stopped breathing, cannot be woken, or has bluish lips or fingertips. Opioid labeling tells clinicians to stress calling 911 or getting emergency help right away when an overdose is known or suspected. The FDA’s 2019 warning lists confusion, extreme sleepiness, slowed, shallow or difficult breathing, and a bluish tint to the lips, fingers or toes as reasons to seek medical attention immediately.

Months of pain and broken nights can wear down anyone’s mood. If that turns into hopelessness or thoughts of suicide, call or text 988 to reach the 988 Suicide & Crisis Lifeline, free and confidential, any hour of the day.

Pain that is new or behaves differently, especially with other new symptoms, belongs in front of a clinician soon rather than in a sleep diary. Our guide to acute and chronic pain lists the warning signs.

The Takeaway

Sleep and pain feed each other, but fixing one does not reliably fix the other. CBT-I gives most people with pain-disrupted nights a real, lasting sleep benefit, including by telephone, while its effect on pain is small and tends to fade. Pain treatment alone rarely repairs sleep. It helps to think of them as two problems with two scores. And when sleep comes up with a clinician, make sure the conversation covers breathing and every sedating medicine you take, not just how many hours you get.

Sources

1. BMC Musculoskeletal Disorders. “Whale K, Dennis J, Wylde V, Beswick A, Gooberman-Hill R. "The effectiveness of non-pharmacological sleep interventions for people with chronic pain: a systematic review and meta-analysis." BMC Musculoskelet Disord, 2022;23(1):440. PubMed. DOI: 10.1186/s12891-022-05318-5.” pubmed.ncbi.nlm.nih.gov
2. The Journal of Pain. “Finan PH, Goodin BR, Smith MT. "The association of sleep and pain: an update and a path forward." J Pain, 2013;14(12):1539-52. PubMed. DOI: 10.1016/j.jpain.2013.08.007.” pubmed.ncbi.nlm.nih.gov
3. Sleep Medicine Reviews. “Chang JR, Fu SN, Li X, et al. "The differential effects of sleep deprivation on pain perception in individuals with or without chronic pain: A systematic review and meta-analysis." Sleep Med Rev, 2022;66:101695. PubMed. DOI: 10.1016/j.smrv.2022.101695.” pubmed.ncbi.nlm.nih.gov
4. National Heart, Lung, and Blood Institute. “NIH HEAL Workshop – Interface Between Sleep and Pain: Symptomatology, Pathobiology, and Treatment Response (December 16-17, 2024).” nhlbi.nih.gov
5. JAMA Internal Medicine. “Scott AJ, Correa AB, Bisby MA, et al. "Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease: A Systematic Review and Meta-Analysis." JAMA Intern Med, 2025;185(11):1350-1361. PubMed. DOI: 10.1001/jamainternmed.2025.4610.” pubmed.ncbi.nlm.nih.gov
6. JAMA Internal Medicine. “McCurry SM, Zhu W, Von Korff M, et al. "Effect of Telephone Cognitive Behavioral Therapy for Insomnia in Older Adults With Osteoarthritis Pain: A Randomized Clinical Trial." JAMA Intern Med, 2021;181(4):530-538. PubMed. DOI: 10.1001/jamainternmed.2020.9049.” pubmed.ncbi.nlm.nih.gov
7. Journal of the American Geriatrics Society. “Yeung K, Zhu W, McCurry SM, et al. "Cost-effectiveness of telephone cognitive behavioral therapy for osteoarthritis-related insomnia." J Am Geriatr Soc, 2022;70(1):188-199. PubMed. DOI: 10.1111/jgs.17469.” pubmed.ncbi.nlm.nih.gov
8. Osteoarthritis and Cartilage. “Hall M, Ferreira P, Eyles J, et al. "Time to wake up to the potential benefits of targeting sleep in osteoarthritis management." Osteoarthritis Cartilage, 2026;34(6):776-783. PubMed. DOI: 10.1016/j.joca.2026.03.122.” pubmed.ncbi.nlm.nih.gov
9. Arthritis & Rheumatology. “Smith MT, Finan PH, Buenaver LF, et al. "Cognitive-behavioral therapy for insomnia in knee osteoarthritis: a randomized, double-blind, active placebo-controlled clinical trial." Arthritis Rheumatol, 2015;67(5):1221-33. PubMed. DOI: 10.1002/art.39048.” pubmed.ncbi.nlm.nih.gov
10. Sleep Medicine Reviews. “Selvanathan J, Pham C, Nagappa M, et al. "Cognitive behavioral therapy for insomnia in patients with chronic pain – A systematic review and meta-analysis of randomized controlled trials." Sleep Med Rev, 2021;60:101460. PubMed. DOI: 10.1016/j.smrv.2021.101460.” pubmed.ncbi.nlm.nih.gov
11. Sleep Medicine Reviews. “Enomoto K, Adachi T, Fujino H, et al. "Comparison of the effectiveness of cognitive behavioral therapy for insomnia, cognitive behavioral therapy for pain, and hybrid cognitive behavioral therapy for insomnia and pain in individuals with comorbid insomnia and chronic pain: A systematic review and network meta-analysis." Sleep Med Rev, 2022;66:101693. PubMed. DOI: 10.1016/j.smrv.2022.101693.” pubmed.ncbi.nlm.nih.gov
12. Pain. “Abolhosseini S, Malatesta A, Asmundson AJN, Gilron I, Salomons TV. "Analgesic benefits of pharmacological and nonpharmacological sleep interventions for adults with fibromyalgia: a systematic review and meta-analyses." Pain, 2025;166(12):2698-2720. PubMed. DOI: 10.1097/j.pain.0000000000003708.” pubmed.ncbi.nlm.nih.gov
13. Rheumatology (Oxford). “Pathak A, Kelleher EM, Brennan I, et al. "Treatments for enhancing sleep quality in fibromyalgia: a systematic review and meta-analysis." Rheumatology (Oxford), 2025;64(8):4495-4516. PubMed. DOI: 10.1093/rheumatology/keaf147.” pubmed.ncbi.nlm.nih.gov
14. National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Fibromyalgia (no review date shown).” niams.nih.gov
15. US Food and Drug Administration. “Morphine sulfate oral solution, full prescribing information (revised 12/2023).” accessdata.fda.gov
16. Anesthesia & Analgesia. “Correa D, Farney RJ, Chung F, Prasad A, Lam D, Wong J. "Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations." Anesth Analg, 2015;120(6):1273-85. PubMed. DOI: 10.1213/ANE.0000000000000672.” pubmed.ncbi.nlm.nih.gov
17. Anesthesia & Analgesia. “Wang D, Yee BJ, Grunstein RR, Chung F. "Chronic Opioid Use and Central Sleep Apnea, Where Are We Now and Where To Go? A State of the Art Review." Anesth Analg, 2021;132(5):1244-1253. PubMed. DOI: 10.1213/ANE.0000000000005378.” pubmed.ncbi.nlm.nih.gov
18. US Food and Drug Administration. “Neurontin, Gralise, Horizant (gabapentin) and Lyrica, Lyrica CR (pregabalin): Drug Safety Communication – Serious Breathing Problems (posted December 19, 2019).” fda.gov
19. US Food and Drug Administration. “FDA is requiring opioid pain medicine manufacturers to update prescribing information regarding long-term use (Drug Safety Communication, July 31, 2025).” fda.gov
20. National Heart, Lung, and Blood Institute. “Insomnia – Diagnosis (last updated March 24, 2022).” nhlbi.nih.gov
21. 988 Suicide & Crisis Lifeline. “988 Suicide & Crisis Lifeline (home page).” 988lifeline.org